These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25182633)

  • 1. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.
    Li X; Wang L; Zhang XJ; Yang Y; Gong WT; Xu B; Zhu YQ; Liu W
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6773-81. PubMed ID: 25182633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii.
    Ikonomidis A; Neou E; Gogou V; Vrioni G; Tsakris A; Pournaras S
    J Clin Microbiol; 2009 Dec; 47(12):4055-9. PubMed ID: 19828742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Smith NM; Lenhard JR; Boissonneault KR; Landersdorfer CB; Bulitta JB; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Clin Microbiol Infect; 2020 Sep; 26(9):1207-1213. PubMed ID: 32061797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
    Liu X; Zhao M; Chen Y; Bian X; Li Y; Shi J; Zhang J
    Int J Antimicrob Agents; 2016 Nov; 48(5):559-563. PubMed ID: 27670371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an
    Beganovic M; Daffinee KE; Luther MK; LaPlante KL
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318006
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
    Wang Y; Li X; Wang D; Sun S; Lu C
    Lett Appl Microbiol; 2020 Mar; 70(3):189-195. PubMed ID: 31808159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
    Sabet M; Tarazi Z; Griffith DC
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.
    Lenhard JR; Bulitta JB; Connell TD; King-Lyons N; Landersdorfer CB; Cheah SE; Thamlikitkul V; Shin BS; Rao G; Holden PN; Walsh TJ; Forrest A; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 Jan; 72(1):153-165. PubMed ID: 27634916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.
    Ceccarelli G; Oliva A; d'Ettorre G; D'Abramo A; Caresta E; Barbara CS; Mascellino MT; Papoff P; Moretti C; Vullo V; Visca P; Venditti M
    BMC Infect Dis; 2015 Sep; 15():393. PubMed ID: 26424078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-baumannii complex isolates from a single hospital in Korea over 7 years.
    Park YK; Jung SI; Park KH; Kim DH; Choi JY; Kim SH; Ko KS
    J Med Microbiol; 2012 Jan; 61(Pt 1):71-79. PubMed ID: 21852525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007.
    Qi C; Malczynski M; Parker M; Scheetz MH
    J Clin Microbiol; 2008 Mar; 46(3):1106-9. PubMed ID: 18216212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.
    Razavi Nikoo H; Ardebili A; Mardaneh J
    Microb Drug Resist; 2017 Sep; 23(6):744-756. PubMed ID: 28085571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.